Skip to main content
News & Conference Highlights

Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB-IIIA NSCLC: ADAURA Exploratory 8-Year Overall Survival Landmark Update

October 15, 2026

Roy S. Herbst, MD, PhD, reviews the exploratory 8-year overall survival landmark update from the phase 3 ADAURA trial of adjuvant osimertinib versus placebo in patients with resected EGFR-mutated stage IB to IIIA non-small cell lung cancer, presented at the 2026 World Conference on Lung Cancer.

Related Posts

Firmonertinib 160 mg Demonstrates Efficacy in EGFR-Mutated NSCLC With Leptomeningeal Mets

September 24, 2026

BH-30643 Shows Activity in EGFR C797S+ NSCLC After Resistance to Prior TKI

September 24, 2026

VRN110755 Elicits Responses With Manageable Safety in EGFR C797S+ NSCLC

September 24, 2026

AMIGO-1 Trial Meets 18-Month PFS End Point With Frontline Amivantamab Triplet in EGFR+ NSCLC Infographic

September 23, 2026

Tags:

Leave a Reply

Funding for the EGFR Channel is provided by AstraZeneca. All content is developed independently by MJH Life Sciences; AstraZeneca has no influence on the content of the site.

© 2026 MJH Life Sciences. All rights reserved.

Home
Clinical Updates Calendar
View All Resources